Vimta Labs
518.55
-6.50(-1.24%)
Market Cap₹2,336.80 Cr
PE Ratio38.41
IndustryHealthcare
Company Performance:
1D-1.24%
1M+12.33%
6M+20.11%
1Y+93.90%
5Y+1,043.94%
View Company Insightsright
Latest news about Vimta Labs
Vimta Labs Reports 35% Surge in Q1 Net Profit, Revenue Up 31%, EBITDA Grows 5 days ago
Vimta Labs announced impressive Q1 financial results, with net profit rising 35% to ₹189.00 crore. Revenue increased by 31% to ₹976.00 crore, while EBITDA grew 30% to ₹337.00 crore. The company's EBITDA margin stood at 34.53%, slightly lower than the previous year's 34.63%. These results indicate significant growth in Vimta Labs' operations and profitability.
Vimta Labs Reports Strong FY25 Results, Targets Revenue of Over Rs. 500 Crore by FY 2025-26 Apr 28, 2025
Vimta Labs Announces 1:1 Bonus Share Issue and Strong Financial Performance Apr 28, 2025
Vimta Labs Reports Strong Q4 FY25 Results, Announces Bonus Shares and Expansion into Biologics Apr 28, 2025
More news about Vimta Labs
23Apr 25
Vimta Labs to Consider Q4 Results, Dividend, and Bonus Share Issue on April 28
Vimta Labs Limited has scheduled a board meeting for April 28, 2025, to approve Q4 and FY2025 financial results, consider dividend payment, and discuss a potential bonus share issue. The company has implemented a trading window closure from April 1, 2025, until 48 hours after the financial results announcement, in compliance with SEBI regulations.
Vimta Labs
518.55
-6.50
(-1.24%)
1 Year Returns:+93.90%
Industry Peers
Syngene International
676.00
(+0.74%)
Indegene
550.40
(-1.97%)
Suven Life Sciences
289.88
(+1.22%)
Vimta Labs
518.55
(-1.24%)
Bilcare
77.56
(+5.00%)
Take Solutions
10.35
(+1.97%)
Adeshwar Meditex
18.00
(0.0%)
Vanta Bioscience
31.33
(+4.61%)